Overview

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally advanced，recurrent or metastatic breast cancer with disease progression following endocrine therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Betta Pharmaceuticals Co., Ltd.

Treatments:

Fulvestrant